Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107

NCT05083260 is registered in ClinicalTrials.gov with BioVie Inc. as lead sponsor.

NCT NCT05083260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05083260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107
Lead sponsor
BioVie Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 4, 2022
Completion date
January 4, 2023
Enrollment
46 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease